Velmanase Alfa: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and TLV (Sweden) recommended or restricted velmanase alfa, while AOTMIT (Poland), DMC (Denmark) and NYE METODER (Norway) did not recommend it.
Assessment has run over 7.8 years, from 8 Feb 2018 at AWMSG (Wales) to 22 Dec 2025 at TLV (Sweden).
CIPM (Spain) changed its position: not recommended on 14 Oct 2020, recommended by 24 Nov 2022, after a resubmission.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 4 of 15 records date from 2023 or later.
AWMSG (Wales) was first to assess velmanase alfa, on 8 Feb 2018; TLV (Sweden) did not open a file until 22 Dec 2025 — a wide spread of 7.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 11 agencies here assessed velmanase alfa more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for velmanase alfa.
The full ledger for velmanase alfa reads 5 not recommended, 4 recommended, 2 restricted and 1 other, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 11 Dec 2024 | Listing (Transparency Committee) | SMR substantial · ASMR IV | source |
| AOTMIT (Poland) | 2 Jan 2024 | Lamzede reimbursement recommendation | not recommended | source |
| NYE METODER (Norway) | 22 Jan 2023 | Behandling av ikke-nevrologiske manifestasjoner hos pasienter med mild til moderat alfa-mannosidose | not introduced | source |
| CIPM (Spain) | 24 Nov 2022 | Indicación terapéutica autorizada: Tratamiento enzimático sustitutivo para controlar las manifestaciones no neurológicas… | financed by the SNS · art. 92 a, c | source |
| SMC (Scotland) | 12 Sep 2022 | Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis. | unknown | source |
10 further decisions for velmanase alfa, across 9 agencies, are not shown here. They include the most recent record on file, 22 Dec 2025 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- teduglutide — same ATC class A16A — Other alimentary tract and metabolism
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 15 decisions for velmanase alfa from 11 agencies, 2018 to 2025. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.